Download PDF
J Reconstr Microsurg 2002; 18(4): 289-294
DOI: 10.1055/s-2002-30185
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Vascularized Bone-Marrow Allotransplantation in Rats Prolongs the Survival of Simultaneously Grafted Alloskin

Yoshihiko Tsuchida1 , Masamichi Usui2 , Toshimitsu Uede3
  • 1Department of Traumatology and Critical Care Medicine, Sapporo Medical Unviersity, Sapporo, Japan
  • 2Higashi Hokkaido Hospital, Kushiro, Japan
  • 3Section of Immunopathogenesis, Institute of Immunological Science, Hokkaido University, Hokkaido, Japan
Further Information

Publication History

Publication Date:
17 May 2002 (online)

    Permissions and Reprints

ABSTRACT

Skin allografts in rats were rejected, even if they were treated with a sub-optimal dose of FK506. However, skin allografts in rats which simultaneously received vascularized limb allografts were rejected more slowly. In this study, the authors examined the reasons why vascularized limb allografts have the ability to induce immunologic tolerance. For investigating which tissue components provide such tolerance, they compared the mean survival times (MST) of skin allografts on the backs of rats (used as an indicator of rejection), which were simultaneously engrafted with vascularized skin allografts, muscle allografts, joint allografts, and limb allografts. In the cases of limb allografts (MST=32.1 days) (these allografts contain bone-marrow cells), the skin allografts survived longer than vascularized skin allografts (MST=23.6 days) or muscle allografts (MST=22.6 days). For ascertaining whether the ability to induce immunologic tolerance of limb allografts was due to bone-marrow cells or not, the authors compared the MST of skin allografts in rats that were simultaneously engrafted with non-irradiated limb allografts, irradiated limb allografts, and bone-marrow cells. The allografted skin in the rats that received non-irradiated limbs (MST=32.1 days) survived longer than irradiated limb allografts (MST=20.3 days) and bone-marrow cells (MST=18.4 days). Limb allografts are, as it were, vascularized bone-marrow allografts. These results suggested that vascularized bone-marrow allografts can facilitate the induction of immunologic tolerance.

KEYWORDS

Bone-marrow allotransplantation - induction of immunologic tolerance - experimental

REFERENCES

  • 1 Hewitt C W, Black K S, Stenger J A. Comparison of kidney, composite tissue, and skin allograft survival in rats prolonged by donor blood and concomitant limited cyclosporine.  Transplant Proc . 1988;  20 1110
    PubMedGoogle Scholar
  • 2 Inamura N, Nakahara K, Kino T. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506.  Transplantation . 1988;  45 206
    PubMedGoogle Scholar
  • 3 Achauer B M, Hewitt C W, Black K S. Cyclosporine prolongs skin allografts in rat burn model.  Transplant Proc . 1983;  15 3073
    PubMedGoogle Scholar
  • 4 Towpik E, Kupiec-Weglinski J W, Tyler D S. Cyclosporine and experimetal skin allografts: long term survival in rats treated with low maintenance doses.  Plast Reconstr Surg . 1986;  77 268
    PubMedGoogle Scholar
  • 5 Lim S ML, Li S Q. Induction of tolerance to vascularized skin allografts using cyclosporine A-an experimental study on rats.  Ann Acad Med . 1991;  20 484
    PubMedGoogle Scholar
  • 6 Watt D J, Patridge T A, Sloper J C. Cyclosporine A as a means of preventing rejection of skeletal muscle allografts in mice.  Transplantation . 1981;  31 266
    PubMedGoogle Scholar
  • 7 Tan C M, Yaremchuk M J, Randolph M A. Vascularized muscle allografts and the role of cyclosporine.  Plast Reconst Surg . 1991;  87 412
    PubMedGoogle Scholar
  • 8 Paskert J P, Yaremchuk M J, Randolph M A, Weiland A J. The role of cyclosporine in prolonged survival in vascularized bone allografts.  Plast Reconstr Surg . 1987;  80 240
    PubMedGoogle Scholar
  • 9 Black K S, Hewitt C W, Fraser L A. Composite tissue (limb) allografts in rats. II. Indefinite survival using low-dose cyclosporine.  Transplantation . 1985;  39 365
    PubMedGoogle Scholar
  • 10 Arai K, Hotokebuchi T, Miyahara H. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival.  Transplantation . 1989;  48 782
    PubMedGoogle Scholar
  • 11 Sakai K, Hickey M J, Hurley J V. Vascularised ostechondral allografts in an immunosuppressed rat model: graft modulation and host immune tolerance.  Plast Reconstr Surg . 1993;  91 597
    PubMedGoogle Scholar
  • 12 Lee W P, Yaremchuk M J, Pan Y C. Relative antigenicity of components of a vascularized limb allograft.  Plast Reconstr Surg . 1991;  87 401
    CrossrefPubMedGoogle Scholar
  • 13 Lee W P, Randolph M A, Weiland A J, Yaremchuk M J. Prolonged survival of vascularized limb tissue allografts by donor irradiation.  J Surg Res . 1995;  59 578
    CrossrefPubMedGoogle Scholar
  • 14 Talmor M, Steinman R M, Codner M A. Bone marrow-derived chimerism in non-irradiated, Cyclosporine-treated rats receiving microvascularized limb transplants: evidence for donor-derived dendritic cells in recipient lymphoid tissues.  Immunology . 1995;  86 448
    PubMedGoogle Scholar
  • 15 Okazaki H, Maki T, Wood M L. Prolongation of skin allograft survival in H-2 K and I region-incompatible mice by pretransplant blood transfusion.  Transplantation . 1981;  32 111
    PubMedGoogle Scholar
  • 16 Opelz G, Graver B, Terasaki P. Induction of high kidney graft survival rate by multiple transfusion.  Lancet . 1981;  1 1223
    PubMedGoogle Scholar
  • 17 Llull R, Murase N, Ye Q. Vascularized bone marrow transplantation in rats: evidence for amplification of hematolymphoid chimerism and freedom from graft-versus-host reaction.  Transplant Proc . 1995;  27 164
    PubMedGoogle Scholar
  • 18 Starzl T E, Demetris A J, Murase N. Cell migration, chimerism, and graft acceptance.  Lancet . 1992;  339 1579
    CrossrefPubMedGoogle Scholar
      >